

To: VICENTE Antonio (CAB-MOEDAS); DEL BRENNIA Giulia (CAB-MOEDAS);
PAQUET Jean-Eric (RTD); BURTSCHER Wolfgang (RTD); NORSTEDT Irene (RTD);
[REDACTED] (RTD); [REDACTED] (RTD); [REDACTED]
[REDACTED] (RTD); [REDACTED] (RTD); [REDACTED] (RTD); [REDACTED]
[REDACTED] (RTD)

Subject: Minutes of the meeting of the Director-General with EFPIA of 7 September 2018

Dear Colleagues,
For your information,
Best wishes,
[REDACTED]

Date:
7 September 2018, 9h00-10h00

Location:
European Commission, ORBN building

Participants:
-European Federation of Pharmaceutical Industries and Associations (EFPIA): [REDACTED]
EFPIA, [REDACTED] EFPIA; [REDACTED] of UCB Pharma), [REDACTED]
[REDACTED] EFPIA);
-European Commission: J-E Paquet (Director-General, DG RTD), W Burtscher (Deputy Director-General, DG RTD), I Norstedt (acting Director for Health, DG RTD), [REDACTED] ([REDACTED]
[REDACTED], DG RTD) [REDACTED] Policy Officer, DG RTD).

Subject and main points discussed:
The meeting was organised at the request of EFPIA representatives to discuss about future partnerships under the next Framework Programme for Research and Innovation, Horizon Europe. EFPIA representatives presented their ideas on how to maximise impact and added value through partnerships in the field of health under Horizon Europe. The Commission representatives pointed out some key requirements for future institutionalised public-private partnerships, notably: clear objectives that deliver impact for the EU and its citizens; appropriate partners and proper governance; and the necessity of in-kind and financial contributions from companies participating.